Abbott Reports Third-Quarter 2015 Results
- Third-quarter adjusted EPS from continuing operations of $0.54; GAAP EPS from continuing operations of $0.39
- Third-quarter double-digit operational sales growth, including double-digit growth in emerging markets
- Narrows full-year 2015 EPS guidance range for continuing operations

ABBOTT PARK, Ill., Oct. 21, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2015.

Abbott 2015 Q3 Performance at-a glance

 

  • Third-quarter worldwide sales of $5.2 billion increased 10.9 percent on an operational basis and 1.4 percent on a reported basis.
  • Adjusted diluted EPS from continuing operations, which excludes specified items, was $0.54 in the third quarter, at the high end of the previous guidance range. Reported diluted EPS from continuing operations under GAAP was $0.39.
  • Abbott narrowed its full-year 2015 adjusted EPS guidance range for continuing operations to $2.14 to $2.16. Projected full-year 2015 EPS for continuing operations under GAAP is $1.59 to $1.61.
  • Abbott achieved double-digit emerging market sales growth on an organic basis, which excludes the impact of 2014 acquisitions and foreign exchange.
  • Abbott continues to deliver improvement in gross margin, while funding investments to expand its innovative product offerings and build new markets. In the third quarter, Abbott launched Similac® Sensitive Non-GMO and Go & Grow by Similac® Non-GMO in the U.S.; and continued the international rollout of its TECNIS® Symfony Extended Range intraocular lens across multiple markets.

"Despite currency headwinds, we are on track to deliver the financial commitments we set at the beginning of the year," said Miles D. White, chairman and chief executive officer, Abbott.  "Our underlying growth is strong and we continue to see robust demand in emerging markets."

THIRD-QUARTER BUSINESS OVERVIEW

Note: Prior year financial results have been adjusted to exclude the sales from Abbott's developed markets branded generics pharmaceuticals and animal health businesses that were sold to Mylan and Zoetis, respectively, in the first quarter 2015. Therefore, sales and growth rates shown in the following charts represent continuing operations.

Following are sales by business segment and commentary for the third quarter and the first nine months of the year:

Total Company
($ in millions)

               

% Change vs. 3Q14

   

Sales 3Q15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total *

 

1,574

 

3,576

 

5,150

 

0.8

 

15.4

 

1.6

 

10.9

 

1.4

Nutrition

 

729

 

1,060

 

1,789

 

(0.7)

 

11.4

 

0.8

 

6.5

 

0.2

Diagnostics

 

348

 

808

 

1,156

 

6.8

 

8.3

 

(5.4)

 

7.9

 

(2.1)

Established Pharmaceuticals

--

 

961

 

961

 

 n/a 

 

42.6

 

24.6

 

42.6

 

24.6

Medical Devices

 

489

 

741

 

1,230

 

(0.8)

 

2.4

 

(11.3)

 

1.2

 

(7.4)

 

* Total Abbott Sales from continuing operations include Other Sales of $14 million.

 

               

% Change vs. 9M14

   

Sales 9M15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total *

 

4,668

 

10,549

 

15,217

 

1.9

 

14.5

 

2.3

 

10.6

 

2.2

Nutrition

 

2,143

 

3,032

 

5,175

 

(0.2)

 

9.7

 

1.0

 

5.5

 

0.5

Diagnostics

 

1,025

 

2,401

 

3,426

 

6.6

 

7.9

 

(4.9)

 

7.5

 

(1.7)

Established Pharmaceuticals

 

--

 

2,835

 

2,835

 

 n/a 

 

43.9

 

29.1

 

43.9

 

29.1

Medical Devices

 

1,479

 

2,266

 

3,745

 

1.9

 

1.7

 

(11.5)

 

1.8

 

(6.7)

 

* Total Abbott Sales from continuing operations include Other Sales of $36 million.

n/a = Not Applicable.

Note: Operational growth reflects percentage change over the prior year excluding the impact of exchange rates.

Third-quarter 2015 worldwide sales of $5.2 billion increased 10.9 percent on an operational basis and 1.4 percent on a reported basis, including an unfavorable 9.5 percent effect of foreign exchange.

International sales increased 15.4 percent on an operational basis and 1.6 percent on a reported basis in the third quarter.

Emerging market sales increased 21.2 percent on an operational basis and 8.2 percent on a reported basis in the third quarter. Excluding the impact of 2014 acquisitions and foreign exchange, emerging market sales increased double digits in the quarter.

Nutrition
($ in millions)        

               

% Change vs. 3Q14

   

Sales 3Q15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

729

 

1,060

 

1,789

 

(0.7)

 

11.4

 

0.8

 

6.5

 

0.2

Pediatric

 

397

 

609

 

1,006

 

3.2

 

14.0

 

4.7

 

9.7

 

4.1

Adult

 

332

 

451

 

783

 

(4.9)

 

8.2

 

(4.1)

 

2.6

 

(4.5)

 

               

% Change vs. 9M14

   

Sales 9M15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

2,143

 

3,032

 

5,175

 

(0.2)

 

9.7

 

1.0

 

5.5

 

0.5

Pediatric

 

1,183

 

1,753

 

2,936

 

3.2

 

10.3

 

3.1

 

7.4

 

3.1

Adult

 

960

 

1,279

 

2,239

 

(4.2)

 

8.8

 

(1.7)

 

3.2

 

(2.8)

 

Worldwide Nutrition sales increased 6.5 percent in the third quarter on an operational basis and 0.2 percent on a reported basis, including an unfavorable 6.3 percent effect of foreign exchange.

Worldwide Pediatric Nutrition sales increased 9.7 percent on an operational basis and 4.1 percent on a reported basis in the quarter, including an unfavorable 5.6 percent effect of foreign exchange. Sales growth in the quarter was led by continued market uptake of Eleva™ in the premium segment of the Chinese market and Similac® Advance® non-GMO in the U.S.  During the quarter, Abbott launched Similac Sensitive Non-GMO and Go & Grow by Similac Non-GMO in the U.S., providing parents with additional formula choices.

Worldwide Adult Nutrition sales increased 2.6 percent on an operational basis and decreased 4.5 percent on a reported basis in the quarter, including an unfavorable 7.1 percent effect of foreign exchange. Further category expansion is driving strong international performance, including double-digit growth in Latin America. As expected, U.S. Adult Nutrition sales were impacted by competitive and market dynamics.

Diagnostics
($ in millions)

               

% Change vs. 3Q14

   

Sales 3Q15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total 

 

348

 

808

 

1,156

 

6.8

 

8.3

 

(5.4)

 

7.9

 

(2.1)

Core Laboratory

 

205

 

720

 

925

 

8.2

 

8.1

 

(5.9)

 

8.1

 

(3.1)

Molecular

 

47

 

66

 

113

 

(7.4)

 

10.4

 

(2.9)

 

2.8

 

(4.8)

Point of Care

 

96

 

22

 

118

 

11.9

 

11.5

 

1.9

 

11.8

 

10.0

 

               

% Change vs. 9M14

   

Sales 9M15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total 

 

1,025

 

2,401

 

3,426

 

6.6

 

7.9

 

(4.9)

 

7.5

 

(1.7)

Core Laboratory

 

596

 

2,142

 

2,738

 

6.3

 

7.3

 

(5.5)

 

7.1

 

(3.2)

Molecular

 

145

 

195

 

340

 

(2.8)

 

12.9

 

(0.7)

 

6.1

 

(1.6)

Point of Care

 

284

 

64

 

348

 

13.1

 

12.2

 

3.6

 

12.9

 

11.2

 

Worldwide Diagnostics sales increased 7.9 percent in the third quarter on an operational basis and decreased 2.1 percent on a reported basis, including an unfavorable 10.0 percent effect of foreign exchange. This business continues to deliver above-market growth across emerging and developed markets, while continuing to expand margins and develop next-generation diagnostic platforms.

Core Laboratory Diagnostics sales increased 8.1 percent in the quarter on an operational basis and decreased 3.1 percent on a reported basis, including an unfavorable 11.2 percent effect of foreign exchange. Operational sales growth in the quarter was led by double-digit growth in emerging markets and continued share gains resulting from customer-focused solutions that help laboratories manage large testing volumes and increase operational efficiencies.

Molecular Diagnostics sales increased 2.8 percent in the quarter on an operational basis and decreased 4.8 percent on a reported basis, including an unfavorable 7.6 percent effect of foreign exchange. Infectious disease testing, which remains Abbott's core focus area in Molecular Diagnostics, increased double digits in the quarter on an operational basis.  As expected, U.S. growth was impacted by the planned scale down of the genetics business and continued market dynamics in oncology.

Point of Care Diagnostics sales increased 11.8 percent in the quarter on an operational basis as this business continues to enhance its product offering and expand its geographic presence. Sales increased 10.0 percent on a reported basis, including an unfavorable 1.8 percent effect of foreign exchange.

Established Pharmaceuticals
($ in millions)

Note: Prior year financial results have been adjusted to exclude the sales from the developed markets branded generics pharmaceuticals business, which was sold to Mylan on Feb. 27, 2015. Therefore, sales and growth rates shown in the following charts represent continuing operations.

               

% Change vs. 3Q14

   

Sales 3Q15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

--

 

961

 

961

 

n/a

 

42.6

 

24.6

 

42.6

 

24.6

Key Emerging Markets

 

--

 

698

 

698

 

n/a

 

37.1

 

18.9

 

37.1

 

18.9

Other

 

--

 

263

 

263

 

n/a

 

60.2

 

42.8

 

60.2

 

42.8

 

               

% Change vs. 9M14

   

Sales 9M15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

--

 

2,835

 

2,835

 

n/a

 

43.9

 

29.1

 

43.9

 

29.1

Key Emerging Markets

 

--

 

2,078

 

2,078

 

n/a

 

41.5

 

26.0

 

41.5

 

26.0

Other

 

--

 

757

 

757

 

n/a

 

51.0

 

38.3

 

51.0

 

38.3

 

Established Pharmaceuticals sales increased 42.6 percent in the third quarter on an operational basis and 24.6 percent on a reported basis, including an unfavorable 18.0 percent effect of foreign exchange.  Excluding the impact of 2014 acquisitions and foreign exchange, sales increased double digits in the quarter.

Sales in Key Emerging Markets increased 37.1 percent on an operational basis and 18.9 percent on a reported basis, including an unfavorable 18.2 percent effect of foreign exchange. Operational sales growth in the quarter was led by India, Russia, Brazil, China, and several markets throughout Latin America.

Medical Devices
($ in millions)

               

% Change vs. 3Q14

   

Sales 3Q15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

489

 

741

 

1,230

 

(0.8)

 

2.4

 

(11.3)

 

1.2

 

(7.4)

Vascular

 

278

 

394

 

672

 

(1.0)

 

1.5

 

(12.0)

 

0.5

 

(7.8)

Diabetes Care

 

98

 

177

 

275

 

(3.8)

 

3.5

 

(10.8)

 

1.0

 

(8.4)

Medical Optics

 

113

 

170

 

283

 

2.6

 

3.1

 

(10.0)

 

3.0

 

(5.3)

                                 

Vascular Product Lines:

                               

Coronary Devicesa)

 

191

 

336

 

527

 

4.8

 

1.1

 

(12.4)

 

2.3

 

(6.8)

Endovascularb)

 

73

 

58

 

131

 

5.8

 

4.0

 

(10.5)

 

4.9

 

(2.1)

                                 

a)Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters, and other coronary products.

b)Includes vessel closure, carotid stents and other peripheral products.

           

 

               

% Change vs. 9M14

   

Sales 9M15

     

Int'l

 

Total

   

U.S.

 

Int'l

 

Total

 

U.S.

 

Operational

 

Reported

 

Operational

 

Reported

Total

 

1,479

 

2,266

 

3,745

 

1.9

 

1.7

 

(11.5)

 

1.8

 

(6.7)

Vascular

 

859

 

1,233

 

2,092

 

3.8

 

0.8

 

(12.2)

 

2.0

 

(6.3)

Diabetes Care

 

293

 

527

 

820

 

(1.1)

 

5.2

 

(9.2)

 

3.0

 

(6.5)

Medical Optics

 

327

 

506

 

833

 

(0.1)

 

0.4

 

(12.3)

 

0.2

 

(7.9)

                                 

Vascular Product Lines:

                               

Coronary Devicesa)

 

571

 

1,055

 

1,626

 

5.2

 

0.1

 

(12.8)

 

1.6

 

(7.2)

Endovascularb)

 

210

 

178

 

388

 

7.3

 

5.4

 

(9.0)

 

6.3

 

(0.9)

                                 

a)Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters, and other coronary products.

b)Includes vessel closure, carotid stents and other peripheral products.

Worldwide Medical Devices sales increased 1.2 percent in the third quarter on an operational basis and decreased 7.4 percent on a reported basis, including an unfavorable 8.6 percent effect of foreign exchange.

Worldwide sales of Vascular products increased 0.5 percent in the quarter on an operational basis and decreased 7.8 percent on a reported basis, including an unfavorable 8.3 percent effect of foreign exchange. Sales of Abbott's MitraClip® device for the treatment of mitral regurgitation increased double digits globally, as Abbott continues to build the market for this first-in-class device. During the quarter, Abbott continued to broaden its foundation as a leader in the treatment of mitral valve disease with the acquisition of Tendyne Holdings Inc. and an option agreement to acquire Cephea Valve Technologies. Abbott also launched XIENCE™ Alpine, its drug-eluting stent system designed for enhanced performance in complex interventions, and Absorb™ GT1, its bioresorbable vascular scaffold, in several markets across Europe and Asia.

Worldwide Diabetes Care sales increased 1.0 percent in the quarter on an operational basis and decreased 8.4 percent on a reported basis, including an unfavorable 9.4 percent effect of foreign exchange. Abbott's FreeStyle® Libre Flash Glucose Monitoring System contributed to international sales growth in the quarter.

Worldwide Medical Optics sales increased 3.0 percent in the quarter on an operational basis and decreased 5.3 percent on a reported basis, including an unfavorable 8.3 percent effect of foreign exchange. Sales of cataract products, which represent approximately 70 percent of Medical Optics sales, increased high single digits, outpacing growth of the global cataract market, led by continued adoption of recently launched products in the premium intraocular lens segment.

ABBOTT NARROWS ITS FULL-YEAR 2015 EARNINGS-PER-SHARE GUIDANCE

Abbott narrowed its full-year 2015 guidance range for earnings per share from continuing operations, excluding specified items, to $2.14 to $2.16. The mid-point of this range remains unchanged from previous guidance.

Abbott forecasts net specified items related to continuing operations for the full year 2015 of approximately $0.55 per share. Specified items include intangible amortization expense, charges associated with cost reduction initiatives, and expenses related to acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock as well as a decrease in the fair value of contingent consideration related to a business acquisition.

Including net specified items, projected earnings per share from continuing operations under U.S. Generally Accepted Accounting Principles (GAAP) would be $1.59 to $1.61 for the full year 2015.

ABBOTT DECLARES 367TH CONSECUTIVE QUARTERLY DIVIDEND

On September 17, 2015, the board of directors of Abbott declared the company's quarterly dividend of $0.24 per share. Abbott's cash dividend is payable on November 15, 2015, to shareholders of record at the close of business on October 15, 2015.

Abbott is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for 25 consecutive years.

About Abbott:

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 73,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Abbott will webcast its live third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the call will be available after 11 a.m. Central time.

Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors,'' to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2014, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Abbott Laboratories and Subsidiaries

Consolidated Statement of Earnings

Third Quarter Ended September 30, 2015 and 2014

(in millions, except per share data)

(unaudited)

 
   

3Q15

 

3Q14

 

% Change

 

Net Sales

 

$5,150

 

$5,079

 

1.4

 
               

Cost of products sold, excluding amortization expense

 

2,242

 

2,319

 

(3.3)

 

Amortization of intangible assets

 

151

 

132

 

14.1

 

Research and development

 

378

 

305

 

23.7

 

Selling, general, and administrative

 

1,666

 

1,595

 

4.5

 

Total Operating Cost and Expenses

 

4,437

 

4,351

 

2.0

 
               

Operating earnings

 

713

 

728

 

(2.0)

 
               

Interest expense, net

 

16

 

17

 

(5.4)

 

Net foreign exchange (gain) loss

 

(14)

 

(1)

 

n/m

 

Other (income) expense, net

 

(3)

 

(3)

 

(12.7)

 

Earnings from Continuing Operations before taxes

 

714

 

715

 

(0.2)

 
               

Taxes on Earnings from Continuing Operations

 

118

 

277

 

(57.2)

 

Earnings from Continuing Operations

 

596

 

438

 

35.8

 
               

Earnings (Loss) from Discontinued Operations, net of taxes

 

(32)

 

100

 

n/m

1)

Gain on Sale of Discontinued Operations, net of taxes

 

16

 

--

 

n/m

 

Net Earnings (Loss) from Discontinued Operations, net of taxes

 

(16)

 

100

 

n/m

1)

               

Net Earnings

 

$580

 

$538

 

7.6

 
               

Net Earnings from Continuing Operations, excluding Specified Items, as described below

             
 

$821

 

$818

 

0.3

2)

               

Diluted Earnings (Loss) per Common Share from:

             

Continuing Operations

 

$0.39

 

$0.29

 

34.5

 

Discontinued Operations

 

(0.01)

 

0.07

 

n/m

1)

Total

 

$0.38

 

$0.36

 

5.6

 
               

Diluted Earnings per Common Share from Continuing 

             

Operations, excluding Specified Items, as described below

 

$0.54

 

$0.54

 

--

2)

               

Average Number of Common Shares Outstanding

             

Plus Dilutive Common Stock Options 

 

1,505

 

1,520

     

 

NOTES:

 

See tables below for an explanation of certain non-GAAP financial information.

 

n/m = Percent change is not meaningful.

 

See footnotes below.

 
 

1)

2014 Earnings and Diluted Earnings per Common Share from Discontinued Operations reflect financial results from the developed markets branded generics pharmaceuticals and animal health businesses, and favorable adjustments to tax expense as a result of the resolution of various tax positions from previous years related to AbbVie operations.

   

2)

2015 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $225 million, or $0.15 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and other expenses related to acquisitions.

   
 

2014 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $380 million, or $0.25 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and deal and other expenses related to the acquisitions, as well as the tax expense associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

Abbott Laboratories and Subsidiaries

Consolidated Statement of Earnings

Nine Months Ended September 30, 2015 and 2014

(in millions, except per share data)

(unaudited)

 
   

9M15

 

9M14

 

% Change

 

Net Sales

 

$15,217

 

$14,891

 

2.2

 
               

Cost of products sold, excluding amortization expense

 

6,541

 

6,881

 

(4.9)

 

Amortization of intangible assets

 

458

 

392

 

16.9

 

Research and development

 

1,036

 

984

 

5.3

 

Selling, general, and administrative

 

5,130

 

4,864

 

5.5

 

Total Operating Cost and Expenses

 

13,165

 

13,121

 

0.3

 
               

Operating earnings

 

2,052

 

1,770

 

15.9

 
               

Interest expense, net

 

49

 

54

 

(8.9)

 

Net foreign exchange (gain) loss

 

(63)

 

--

 

n/m

 

Other (income) expense, net

 

(287)

 

2

 

n/m

1)

Earnings from Continuing Operations before taxes

 

2,353

 

1,714

 

37.2

 
               

Taxes on Earnings from Continuing Operations

 

442

 

627

 

(29.5)

 

Earnings from Continuing Operations

 

1,911

 

1,087

 

75.7

 
               

Earnings (Loss) from Discontinued Operations, net of taxes

 

(7)

 

293

 

n/m

 

Gain on Sale of Discontinued Operations, net of taxes

 

1,752

 

--

 

n/m

 

Net Earnings from Discontinued Operations, net of taxes

 

1,745

 

293

 

n/m

2)

               

Net Earnings

 

$3,656

 

$1,380

 

165.0

 
               

Net Earnings from Continuing Operations, excluding 

             

Specified Items, as described below

 

$2,326

 

$2,094

 

11.0

3)

               

Diluted Earnings per Common Share from:

             

Continuing Operations

 

$1.26

 

$0.71

 

77.5

 

Discontinued Operations

 

1.15

 

0.19

 

n/m

2)

Total

 

$2.41

 

$0.90

 

n/m

 
               

Diluted Earnings per Common Share from Continuing 

             

Operations, excluding Specified Items, as described below

 

$1.53

 

$1.36

 

12.5

3)

               

Average Number of Common Shares Outstanding

             

Plus Dilutive Common Stock Options 

 

1,509

 

1,529

     

 

NOTES:

 

See tables below for an explanation of certain non-GAAP financial information.

 

n/m = Percent change is not meaningful.

 

See footnotes below.

 

1)

2015 Other (income) expense includes a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, both reported as specified items.

   

2)

2015 Earnings and Diluted Earnings per Common Share from Discontinued Operations reflect the after-tax gain of $1.752 billion on the sale of the developed markets branded generics pharmaceuticals and animal health businesses to Mylan on Feb. 27, 2015 and Zoetis on Feb. 10, 2015, respectively; the first-quarter financial results from these businesses up to the date of sale; and an unfavorable adjustment to tax expense as a result of the resolution of various tax positions from previous years related to AbbVie operations. 

   
 

2014 Earnings and Diluted Earnings per Common Share from Discontinued Operations reflect financial results from the developed markets branded generics pharmaceuticals and animal health businesses, and favorable adjustments to tax expense as a result of the resolution of various tax positions from previous years related to AbbVie operations and the developed markets branded generics pharmaceuticals business.

   

3)

2015 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $415 million, or $0.27 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and other expenses related to acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition.

   
 

2014 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $1.007 billion, or $0.65 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and deal and other expenses related to acquisitions, as well as the tax expense associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

NON-GAAP RECONCILIATION OF FINANCIAL INFORMATION FROM CONTINUING OPERATIONS

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Third Quarter Ended September 30, 2015 and 2014

(in millions, except per share data) 

(unaudited)

 
   

3Q15

   

As
Reported
(GAAP) 

 

Specified
Items

 

As
Adjusted

 

% to
Sales

                 

Intangible Amortization

 

$151

 

($151)

 

--

   

Gross Margin

 

2,757

 

206

 

2,963

 

57.5%

R&D

 

378

 

(59)

 

319

 

6.2%

SG&A

 

1,666

 

(46)

 

1,620

 

31.4%

Other (Income) Expense, Net

 

(3)

 

12

 

9

   

Earnings from Continuing Operations before taxes 

 

714

 

299

 

1,013

   

Taxes on Earnings from Continuing Operations

 

118

 

74

 

192

   

Net Earnings from Continuing Operations

 

596

 

225

 

821

   

Diluted Earnings per Share from Continuing Operations

 

$0.39

 

$0.15

 

$0.54

   

 

Specified items reflect intangible amortization expense of $151 million and other expenses of $148 million, primarily associated with cost reduction initiatives and acquisitions.

   

3Q14

   

Historical GAAP
Adj for Disc Ops 1)

 

Specified
Items

 

As
Adjusted 

 

% to Sales

                 

Intangible Amortization

 

$132

 

($132)

 

--

   

Gross Margin

 

2,628

 

188

 

2,816

 

55.4%

R&D

 

305

 

(2)

 

303

 

6.0%

SG&A

 

1,595

 

(100)

 

1,495

 

29.4%

Other (Income) Expense, Net

 

(3)

 

(4)

 

(7)

   

Earnings from Continuing Operations before taxes

 

715

 

294

 

1,009

   

Taxes on Earnings from Continuing Operations

 

277

 

(86)

 

191

   

Net Earnings from Continuing Operations

 

438

 

380

 

818

   

Diluted Earnings per Share from Continuing Operations

 

$0.29

 

$0.25

 

$0.54

   
   

1)

Historical GAAP financial results, adjusted for the discontinued operations, as previously reported in Abbott's 8-K filing dated Jan. 27, 2015.

 

Specified items reflect intangible amortization expense of $132 million and other expenses of $162 million, primarily associated with cost reduction initiatives and deal and other expenses related to acquisitions, as well as tax expense of $110 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Nine Months Ended September 30, 2015 and 2014

(in millions, except per share data) 

(unaudited)

 
   

9M15

   

As
Reported
(GAAP) 

 

Specified
Items

 

As
Adjusted

 

% to
Sales

                 

Intangible Amortization

 

$458

 

($458)

 

--

   

Gross Margin

 

8,218

 

577

 

$8,795

 

57.8%

R&D

 

1,036

 

(81)

 

955

 

6.3%

SG&A

 

5,130

 

(155)

 

4,975

 

32.7%

Other (Income) Expense, Net

 

(287)

 

294

 

7

   

Earnings from Continuing Operations before taxes 

 

2,353

 

519

 

2,872

   

Taxes on Earnings from Continuing Operations

 

442

 

104

 

546

   

Net Earnings from Continuing Operations

 

1,911

 

415

 

2,326

   

Diluted Earnings per Share from Continuing Operations

 

$1.26

 

$0.27

 

$1.53

   

 

Specified items reflect intangible amortization expense of $458 million and other expenses of $348 million, primarily associated with cost reduction initiatives and acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock of $207 million and a decrease in the fair value of contingent consideration related to a business acquisition.

   

9M14

   

Historical GAAP
Adj for Disc Ops 1)

 

Specified
Items

 

As
Adjusted 

 

% to Sales

                 

Intangible Amortization

 

$392

 

($392)

 

--

   

Gross Margin

 

7,618

 

530

 

8,148

 

54.7%

R&D

 

984

 

(53)

 

931

 

6.3%

SG&A

 

4,864

 

(280)

 

4,584

 

30.8%

Other (Income) Expense, Net

 

2

 

(8)

 

(6)

   

Earnings from Continuing Operations before taxes

 

1,714

 

871

 

2,585

   

Taxes on Earnings from Continuing Operations

 

627

 

(136)

 

491

   

Net Earnings from Continuing Operations

 

1,087

 

1,007

 

2,094

   

Diluted Earnings per Share from Continuing Operations

 

$0.71

 

$0.65

 

$1.36

   
   

1)

Historical GAAP financial results, adjusted for the discontinued operations, as previously reported in Abbott's 8-K filing dated Jan. 27, 2015.

 

Specified items reflect intangible amortization expense of $392 million and other expenses of $479 million, primarily associated with cost reduction initiatives and deal and other expenses related to acquisitions, as well as tax expense of $264 million associated with a one-time repatriation of 2014 ex-U.S. earnings.


RECONCILIATION OF TAX RATE FOR CONTINUING OPERATIONS

A reconciliation of the third-quarter tax rates for continuing operations for 2015 and 2014 is shown below:

     

3Q15

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

As reported (GAAP)

 

$714

 

$118

 

16.6%

 

Specified items

 

299

 

74

     

Excluding specified items

 

$1,013

 

$192

 

19.0%

 
                 
                 
     

3Q14

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

As reported (GAAP)

 

$715

 

$277

 

38.7%

1)

Specified items

 

294

 

(86)

     

Excluding specified items

 

$1,009

 

$191

 

19.0%

 
   

1)

Reported tax rate on a GAAP basis includes the impact of tax expense of $110 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

A reconciliation of the year-to-date tax rates for continuing operations for 2015 and 2014 is shown below:

     

9M15

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

As reported (GAAP)

 

$2,353

 

$442

 

18.8%

 

Specified items

 

519

 

104

     

Excluding specified items

 

$2,872

 

$546

 

19.0%

 
                 
                 
     

9M14

 

($ in millions)

 

Pre-Tax
Income

 

Taxes on
Earnings

 

Tax
Rate

 

As reported (GAAP)

 

$1,714

 

$627

 

36.6%

2)

Specified items

 

871

 

(136)

     

Excluding specified items

 

$2,585

 

$491

 

19.0%

 
   

2)

Reported tax rate on a GAAP basis includes the impact of tax expense of $264 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

Abbott Logo

Photo - http://photos.prnewswire.com/prnh/20151020/278966-INFO
Logo - http://photos.prnewswire.com/prnh/20150928/271488LOGO

 

SOURCE Abbott

For further information: Abbott Financial: Scott Leinenweber, (224) 668-0791, Michael Comilla, (224) 668-1872, Jeffrey Byrne, (224) 668-8808, Abbott Media: Scott Stoffel, (224) 668-5201
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

yesno
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

yesno